Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | RARB | P10826 | 4/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.64 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | THRA | P10827 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7732272 | 1.00 | L3MBTL1 (0.77) | L3MBTL1RARBGAATP53TSHR | |
| SCHEMBL9000300 | 0.98 | GAA (0.77) | L3MBTL1RARBGAATP53TSHR | |
| SCHEMBL7739031 | 0.98 | GAA (0.77) | L3MBTL1RARBGAATP53TSHR | |
| SCHEMBL9126821 | 0.98 | GAA (0.77) | L3MBTL1RARBGAATP53TSHR | |
| SCHEMBL9637119 | 0.98 | GAA (0.77) | L3MBTL1RARBGAATP53TSHR | |
| SCHEMBL7732601 | 0.98 | GAA (0.77) | L3MBTL1RARBGAATP53TSHR | |
| SCHEMBL10536554 | 0.98 | GAA (0.77) | L3MBTL1RARBGAATP53TSHR | |
| SCHEMBL12243177 | 0.98 | GAA (0.77) | L3MBTL1RARBGAATP53TSHR | |
| SCHEMBL15177348 | 0.98 | GAA (0.77) | L3MBTL1RARBGAATP53TSHR | |
| SCHEMBL7733807 | 0.97 | L3MBTL1 (0.76) | L3MBTL1RARBGAATP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3677252-A1 | DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | CIDARA THERAPEUTICS, INC. (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-2827710-B1 | DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | CIDARA THERAPEUTICS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20170151306-A1 | DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | NAPP PHARMACEUTICAL GROUP LIMITED (GB) | 2017-06-01 | — | — | US | disclosed |
| US-9526835-B2 | Dosing regimens for echinocandin class compounds | CIDARA THERAPEUTICS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9056897-B2 | Method for isolating a cyclohexapeptide | DSM Sinochem Pharmaceuticals (NL) | 2015-06-16 | — | — | US | disclosed |
| US-20150087583-A1 | DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | CIDARA THERAPEUTICS, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| EP-2350119-B1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | UNIQUEST PTY LTD (AU) | 2014-10-29 | — | — | EP | disclosed |
| US-20130184433-A1 | METHOD FOR ISOLATING A CYCLOHEXAPEPTIDE | DSM Sinochem Pharmaceuticals (NL) | 2013-07-18 | — | — | US | disclosed |
| US-20130184433-A1 | METHOD FOR ISOLATING A CYCLOHEXAPEPTIDE | DSM Sinochem Pharmaceuticals (NL) | 2013-07-18 | — | — | US | disclosed |
| WO-2012041801-A1 | METHOD FOR ISOLATING A CYCLOHEXAPEPTIDE | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| US-7790744-B2 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-6743777-B1 | TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | VIP, LTA, CLPTM1 | L3MBTL1 690/4885RARB 2792/4885GAA 1148/4885 |
| US-20170151306-A1 | DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | XPO5, XPO1, CYP3A5 | L3MBTL1 4780/4885RARB 4586/4885GAA 1243/4885 |
| US-20150087583-A1 | DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | XPO5, XPO1, CYP3A5 | L3MBTL1 4780/4885RARB 4586/4885GAA 1243/4885 |
| US-20130184433-A1 | METHOD FOR ISOLATING A CYCLOHEXAPEPTIDE | VIP, CASP6, CASP14 | L3MBTL1 3943/4885RARB 4858/4885GAA 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.